Viewing data from:

XPOVIO

NDA

SELINEXOR | N212306 | KARYOPHARM THERAPEUTICS INC

6 strengths11 unique patents6 unique exclusivities

Patent Timeline

11 unique patents, 6 exclusivities by expiration date

Active (11)TodayExclusivity

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

Today

Jul. 3, 2033

Jul. 26, 2032

Jul. 26, 2032

Aug. 14, 2035

Jul. 26, 2032

Jul. 26, 2032

Aug. 14, 2035

Aug. 14, 2035

Jul. 26, 2032

Aug. 14, 2035

Jul. 26, 2032

ODE-257

Jul. 3, 2026

ODE*

Jul. 3, 2026

ODE-310

Jun. 22, 2027

ODE*

Jun. 22, 2027

ODE-346

Dec. 18, 2027

ODE*

Dec. 18, 2027

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

90 trials from ClinicalTrials.gov — 9 recruiting, 13 active, 43 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma NCT02436707	Phase 2	Active	Canadian Cancer Trials Group	129	2015-10-27 → 2026-12-31
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML NCT02091245	Phase 1	Active	Dana-Farber Cancer Institute	16	2014-03 → 2026-12
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis NCT04562870	Phase 2	Active	Karyopharm Therapeutics Inc	112	2021-03-17 → 2026-09
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma NCT06169215	Phase 2	Active	National Cancer Institute (NCI)	70	2024-07-23 → 2026-09-30
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06158841	Phase 3	Active	AbbVie	421	2024-05-19 → 2027-12
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222	Phase 2	Active	PETHEMA Foundation	62	2018-07-15 → 2026-08
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma NCT03147885	Phase 1/2	Active	Barbara Ann Karmanos Cancer Institute	43	2017-06-20 → 2027-12
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients NCT02835222	Phase 2	Active	Wake Forest University Health Sciences	57	2018-02-02 → 2027-04-18
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT NCT07779031	Phase 1/2	Active	Liping Dou	58	2025-05-01 → 2028-05-01
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma NCT05611931	Phase 3	Active	Karyopharm Therapeutics Inc	257	2023-04-18 → 2028-01

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

VA Federal Supply Schedule

Government-negotiated contract prices | 14 NDCs (7 FSS, 7 Big4)

Lowest Price

$17571.07

Highest Price

$29656.58

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
72237-0101-03XPOVIO 20MG X 3 (60MG) BI-WEEKLY PKT	$17571.07	Big4	Karyopharm Therapeutics Inc.	03/31/2026
72237-0101-03XPOVIO 20MG X 3 (60MG) BI-WEEKLY PKT	$28041.56	FSS	Karyopharm Therapeutics Inc.	03/31/2026
72237-0101-04XPOVIO 20MG X 4 (80MG) BI-WEEKLY PKT	$20583.41	Big4	Karyopharm Therapeutics Inc.	03/31/2026
72237-0101-04XPOVIO 20MG X 4 (80MG) BI-WEEKLY PKT	$28041.56	FSS	Karyopharm Therapeutics Inc.	03/31/2026
72237-0102-02XPOVIO 80MG WEEKLY PKT	$21856.93	Big4	Karyopharm Therapeutics Inc.	03/31/2026
72237-0102-02XPOVIO 80MG WEEKLY PKT	$28041.56	FSS	Karyopharm Therapeutics Inc.	03/31/2026

Showing 6 of 14 NDCs.

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Xpovio (2024)

Total Spending

$98.2M

Total Claims

3,428

Beneficiaries

1,103

Avg Cost/Unit

$6013.16

Spending Trend

$16.2M(2019)→$48.7M(2020)→$69.6M(2021)→$86.8M(2022)→$85.6M(2023)→$98.2M(2024)

YoY Change:+13.9%

5yr CAGR:+46.1%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

8 letters from Drugs@FDA

Date	Submission	Document
May 4, 2026	SUPPL -18	View Letter (PDF)
Sep 30, 2025	SUPPL -16	View Letter (PDF)
Mar 12, 2025	SUPPL -13	View Letter (PDF)
Jul 18, 2022	SUPPL -11	View Letter (PDF)
Mar 29, 2022	SUPPL -10	View Letter (PDF)
Dec 23, 2020	ORIG -1	View Letter (PDF)
Dec 22, 2020	SUPPL -5	View Letter (PDF)
Jun 23, 2020	SUPPL -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (6)

Sort:

#001 — 20MG

RLD

11 patents3 exclusivities▴

TABLET;ORAL | Approved: Jul 3, 2019

Patents (11) · 17 use codes

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8999996	Jul 3, 2033	—	Yes	Yes	—	—
9079865	Jul 26, 2032	—	—	—		—
9714226	Jul 26, 2032	—	Yes	Yes	—	—
10519139	Aug 14, 2035	—	Yes	Yes		—
10544108	Jul 26, 2032	—	—	—		—
11034660	Jul 26, 2032	—	—	—		—
11746102	Aug 14, 2035	—	—	—		—
11753401	Aug 14, 2035	—	—	Yes		—
11787771	Jul 26, 2032	—	—	—		—
11807629	Aug 14, 2035	—	Yes	Yes	—	—
12291508	Jul 26, 2032	—	—	—		—

Exclusivities (3)

Code	Date	Status
ODE-257	Jul 3, 2026	Expired
ODE-310	Jun 22, 2027	< 1 year
ODE-346	Dec 18, 2027	Active

#002 — 40MG

RLD

11 patents3 exclusivities▾

TABLET;ORAL | Approved: Apr 15, 2021

#003 — 50MG

RLD

11 patents3 exclusivities▾

TABLET;ORAL | Approved: Apr 15, 2021

#004 — 60MG

RLD

11 patents3 exclusivities▾

TABLET;ORAL | Approved: Apr 15, 2021

#005 — 10MG

RLD

11 patents3 exclusivities▾

TABLET;ORAL | Approved: Mar 10, 2025

#006 — 80MG

RLD

11 patents2 exclusivities▾

TABLET;ORAL | Approved: Oct 20, 2025